Skip to main content
. 2024 Sep 16;32(4):101342. doi: 10.1016/j.omtm.2024.101342

Figure 6.

Figure 6

Knockdown of GRIK2 following administration of AAV9-aGRIK2 is restricted to the hippocampus

(A) Expression level of miR1 and (B) miR2 after intra-hippocampal administration of AAV9-aGRIK2 at 1.2E+12 gc/hippocampus. (C) Expression levels of miR1 and (D) miR2 in different brain regions after administration AAV9-aGRIK2 at 6.0E+10 gc/hippocampus, 2.4E+11 gc/hippocampus and 1.2E+12 gc/hippocampus. (E) Correlation between vector copies and miR1 or (F) miR2 expression. (G) Detection of miR2 in the CSF after administration of AAV9-aGRIK2 at 6.0E+10 gc/hippocampus, 2.4E+11 gc/hippocampus and 1.2E+12 gc/hippocampus. (H) Expression levels of GRIK2 mRNA in the hippocampus and EC after administration AAV9-aGRIK2 at 6.0E+10 gc/hippocampus, 2.4E+11 gc/hippocampus, and 1.2E+12 gc/hippocampus compared with the diluent. (I) Correlation between combined expression of the two miRNAs and the vector DNA. Data are reported as mean ± SEM.